Glomerular cell death and inflammation with high-protein diet and diabetes

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1711-1720

  Meek, Rick L ^a   LeBoeuf, Renee C ^b   Saha, Sandeep A ^a,b   Alpers, Charles E ^b   Hudkins, Kelly L ^b   Cooney, Sheryl K ^a   Anderberg, Robert J ^a   Tuttle, Katherine R ^a,b  

^a SACRED HEART MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; High protein diet; Mesangial cells; Podocytes; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID A PROTEIN; CASPASE 3; CASPASE 4; CASPASE 7; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MESANGIUM CELL; METABOLIC STRESS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NICK END LABELING; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN EXPRESSION; PROTEIN INTAKE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINALYSIS;

APOPTOSIS; HIGH-PROTEIN DIET; MESANGIAL CELLS; PODOCYTES; RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET; DIETARY PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; PODOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84877255276     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs579     Document Type: Article

References (50)

1. National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S1-S179
2. United States Renal Data System UADR. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, 2011
3. Hostetter TH, Meyer TW, Rennke HG et al. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 1986; 30: 509-517
4. Zatz R, Meyer TW, Rennke HG et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963-5967
5. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006; 1: 1293-1299
6. Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr Drug Targets 2009; 10: 42-50
7. Hofmann SM, Dong HJ, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002; 51: 2082-2089
8. Zheng F, He C, Cai W et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002; 18: 224-237
9. Stenvinkel P, Carrero JJ, Axelsson J et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521
10. Semba RD, Ferrucci L, Fink JC et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 2009; 53: 51-58
11. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3: 101-108
12. Banba N, Nakamura T, Matsumura M et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000; 58: 684-690
13. Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808
14. Zhou LL, Cao W, Xie C et al. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int 2012; 82: 759-770
15. Dong Z, Wu T, Qin W et al. Serum amyloid a directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med 2011; 17: 1357-1364
16. Filep JG, El Kebir D. Serum amyloid A as a marker and mediator of acute coronary syndromes. Future Cardiol 2008; 4: 495-504
17. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011; 22: 302-307
18. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14:10-22
19. Chow FY, Nikolic-Paterson DJ, Ozols E et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80
20. Wada T, Pippin JW, Terada Y et al. The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int 2005; 68: 1618-1629
21. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
22. Coughlan MT, Thallas-Bonke V, Pete J et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007; 148: 886-895
23. Guo S, Kowalewska J, Wietecha TA et al. Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol 2008; 19: 1168-1176
24. Weibel ER. Practical Methods for Biological Morphometry. London: Academic Press, 1979, pp. 40-116
25. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348
26. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104-2113
27. Macconi D, Bonomelli M, Benigni A et al. Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 2006; 168: 42-54
28. Saha SA, LaSalle BK, Clifton GD et al. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study. Am J Ther 2010; 17: 553-558
29. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27: 58-65
30. Brosius FC, Alpers CE, Bottinger EP et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-2512
31. Tuttle KR, Anderberg RJ, Cooney SK et al. Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet. Am J Nephrol 2009; 29: 171-180
32. Tuttle KR, Johnson EC, Cooney SK et al. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int 2005; 67: 953-968
33. Herman-Edelstein M, Thomas MC, Thallas-Bonke V et al. Dedifferentiation of immortalized human podocytes in response to transforming growth factor-beta: a model for diabetic podocytopathy. Diabetes 2011; 60: 1779-1788
34. Li JJ, Kwak SJ, Jung DS et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007; 72: S36-S42
35. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233
36. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: 26-31
37. Tuttle KR, Milton JE, Packard DP et al. Dietary amino acids and blood pressure: a cohort study of patients with cardiovascular disease. Am J Kidney Dis 2012; 59: 803-809
38. Xu ZG, Yoo TH, Ryu DR et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int 2005; 67: 944-952
39. Rüster C, Bondeva T, Franke S et al. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008; 23: 2179-2191
40. Meek RL, Benditt EP. Amyloid A gene family expression in different mouse tissues. J Exp Med 1986; 164: 2006-2017
41. Upragarin N, Landman WJ, Gaastra W et al. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol 2005; 20: 1295-1307
42. Urieli-Shoval S, Cohen P, Eisenberg S et al. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 1998; 46: 1377-1384
43. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003; 284: F1121-F1137
44. Brune B, Sandau K, von Knethen A. Apoptotic cell death and nitric oxide: activating and antagonistic transducing pathways. Biochemistry (Mosc) 1998; 63: 817-825
45. Chung HT, Pae HO, Choi BM et al. Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 2001; 282: 1075-1079
46. Sugimoto H, Shikata K, Wada J et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-886
47. Bremer V, Tojo A, Kimura K et al. Role of nitric oxide in rat nephrotoxic nephritis: comparison between inducible and constitutive nitric oxide synthase. J Am Soc Nephrol 1997; 8: 1712-1721
48. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-255
49. Mullan RH, McCormick J, Connolly M et al. A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. Am J Pathol 2010; 176: 1999-2008
50. Okamura DM, Pennathur S, Pasichnyk K et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol 2009; 20: 495-505